当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

Abstract：

:The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antigens are also discussed which may provide potential target molecules. The human carcinoembryonic antigen (CEA), which is expressed on approximately 50% of breast cancers, represents one such target for immunotherapy. To enhance the immunogenicity of this antigen, a recombinant CEA-vaccinia vaccine, designated rV-CEA, was produced. To study the effects of this vaccine in an animal model, a murine colon carcinoma cell line was transduced with CEA and transplanted into immunocompetent mice for protection and therapy studies. Pre-clinical toxicity studies were also conducted in non-human primates. The results of these studies showed the rV-CEA vaccine to be immunogenic and safe in both rodents and primates, and to elicit good anti-tumor responses in the rodent model. In a Phase I clinical trial in metastatic breast, lung, and colorectal cancer patients involving three immunizations of rV-CEA, at three dose levels, enhancement of T-cell and antibody responses to vaccinia virus proteins were observed with no toxicity. Specific T-cell responses were studied via stimulation of peripheral blood lymphocytes with specific peptide epitopes from the CEA molecule. These studies demonstrated clear cut differences in establishment of T-cell lines pre- versus post-immunization. The T-cell lines were shown to be CD8+ and/or CD4+/CD8+, to lyse EBV transformed B-cells transduced with the CEA gene, and to lyse CEA positive carcinoma cells in a HLA restricted manner. Thus, in a Phase I clinical trial the rV-CEA vaccine has been shown to stimulate a CTL response specific for CEA defined epitopes in cancer patients.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

doi

10.1007/BF01803781

subject

Has Abstract

pub_date

1996-01-01 00:00:00

pages

27-39

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

38

pub_type

杂志文章,评审

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines.

    abstract：:Proliferation of both mouse and human breast cancer cells was inhibited by chlorpheniramine (CPA) in a dose-response manner. At the beginning of the exponential phase of growth (two days after seeding), 250 microM CPA was able to reduce cell proliferation by 75% (in Ehrlich cell cultures) and 30% (in MCF-7 cultures). ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00668208

    authors： Medina MA,García de Veas R,Morata P,Lozano J,Sánchez-Jiménez F

    更新日期：1995-08-01 00:00:00

  • Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure.

    abstract：BACKGROUND:The Z0011 trial initiated a paradigm shift in the axillary treatment of breast cancer patients with a positive sentinel lymph node biopsy (SLNB), disregarding patients with a positive ultrasound-guided lymph node biopsy (UGLNB). We examined whether relevant differences exist between these patients to determi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4342-1

    authors： Verheuvel NC,Voogd AC,Tjan-Heijnen VCG,Siesling S,Roumen RMH

    更新日期：2017-10-01 00:00:00

  • Polyamines metabolism and breast cancer: state of the art and perspectives.

    abstract：:Breast cancer (BC) is a common disease that generally occurs in women over the age of 50, and the risk is especially high for women over 60 years of age. One of the major BC therapeutic problems is that tumors initially responsive to chemotherapeutic approaches can progress to more aggressive forms poorly responsive t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-014-3156-7

    authors： Cervelli M,Pietropaoli S,Signore F,Amendola R,Mariottini P

    更新日期：2014-11-01 00:00:00

  • A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk.

    abstract：:In this paper, we report findings from a family-based association study examining the association between polymorphisms in two key estrogen-metabolism genes CYP1B1 (codon 432 G --> C and codon 453 A --> G variants) and COMT (codon 158 G --> A variant) and female breast cancer. We conducted the study among 280 nuclear ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000025401.60794.68

    authors： Ahsan H,Chen Y,Whittemore AS,Kibriya MG,Gurvich I,Senie RT,Santella RM

    更新日期：2004-05-01 00:00:00

  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract：:Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005951125574

    authors： Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期：1998-03-01 00:00:00

  • Structural and functional studies of insulin receptors in human breast cancer.

    abstract：:We characterized the structure and the function of insulin receptors isolated from 10 human breast cancer specimens. We observed that the insulin receptor content, as determined by a specific radioimmunoassay, was four fold increased in human breast cancer tissue when compared to normal breast tissues. In both cancer ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00662403

    authors： Frittitta L,Vigneri R,Papa V,Goldfine ID,Grasso G,Trischitta V

    更新日期：1993-01-01 00:00:00

  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.

    abstract：PURPOSE:Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2-/cHER2+ can benefit from anti-HER2 targeted therapies. METHODS:cHER2 status was determined in 105 advanced-stage patient...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05662-x

    authors： Wang C,Mu Z,Ye Z,Zhang Z,Abu-Khalaf MM,Silver DP,Palazzo JP,Jagannathan G,Fellin FM,Bhattacharya S,Jaslow RJ,Tsangaris TN,Berger A,Neupane M,Cescon TP,Lopez A,Yao K,Chong W,Lu B,Myers RE,Hou L,Wei Q,Li B,Cri

    更新日期：2020-06-01 00:00:00

  • Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?

    abstract：PURPOSE:Primary chemotherapy is commonly used in patients with breast cancer to downstage the primary tumour prior to surgery. There is a need to establish, prior to commencement of chemotherapy, predictors of clinical and pathological response, which may then be surrogate markers for patient survival and thus allow id...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/B:BREA.0000032986.00879.d7

    authors： Ogston KN,Miller ID,Schofield AC,Spyrantis A,Pavlidou E,Sarkar TK,Hutcheon AW,Payne S,Heys SD

    更新日期：2004-07-01 00:00:00

  • Novel triterpenoid 25-hydroxy-3-oxoolean-12-en-28-oic acid induces growth arrest and apoptosis in breast cancer cells.

    abstract：:25-Hydroxy-3-oxoolean-12-en-28-oic acid (Amooranin-AMR) is a triterpene acid isolated from the stem bark of a tropical tree (Amoora rohituka) grown wild in India. A herbal preparation used for the treatment of cancer by the Ayurvedic system of medicine contains the stem bark of Amoora rohituka as one of the ingredient...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9275-z

    authors： Rabi T,Wang L,Banerjee S

    更新日期：2007-01-01 00:00:00

  • Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use.

    abstract：:Preclinical and epidemiologic evidence supports a possible role for beta-adrenergic blocking drugs (beta-blockers), and angiotensin-converting enzyme inhibitors (ACEIs) in promoting survival after breast cancer. However, these drugs are often used concurrently with aspirin, and there is a growing body of evidence indi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2553-7

    authors： Holmes MD,Hankinson SE,Feskanich D,Chen WY

    更新日期：2013-06-01 00:00:00

  • Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

    abstract：PURPOSE:Estrogen exposure is involved in both breast cancer susceptibility and the prognosis in patients with breast cancer. Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis. The aim of this study was to examine the effect of single nucleotide pol...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9822-2

    authors： Fasching PA,Loehberg CR,Strissel PL,Lux MP,Bani MR,Schrauder M,Geiler S,Ringleff K,Oeser S,Weihbrecht S,Schulz-Wendtland R,Hartmann A,Beckmann MW,Strick R

    更新日期：2008-11-01 00:00:00

  • Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.

    abstract：PURPOSE:In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1-T2 cN0 early breast cancer and 1-2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3-...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05876-z

    authors： Riedel F,Heil J,Feisst M,Moderow M,von Au A,Domschke C,Michel L,Schaefgen B,Golatta M,Hennigs A

    更新日期：2020-11-01 00:00:00

  • Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis.

    abstract：:Progression of breast cancer from an estrogen-dependent, slowly growing tumor amenable to tamoxifen treatment to an aggressive, metastatic, estrogen-independent phenotype has been mimicked by the transfection of MCF-7 breast carcinoma cells with fibroblast growth factors 1 or 4. FGF-transfected cells are aggressively ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806082

    authors： McLeskey SW,Zhang L,Kharbanda S,Kurebayashi J,Lippman ME,Dickson RB,Kern FG

    更新日期：1996-01-01 00:00:00

  • Is there a role for sentinel node biopsy in the pre-operative ultrasound positive axilla?

    abstract：:Axillary management in breast cancer is becoming increasingly conservative. This approach is based on the identification of low axillary burden on sentinel node biopsy (SNB). The modern practice of routine pre-operative axillary ultrasound has meant that patients are 'fast tracked' to axillary node clearance (ANC) in ...

    journal_title：Breast cancer research and treatment

    pub_type： 社论

    doi：10.1007/s10549-017-4313-6

    authors： Ahmed M,Jozsa F,Douek M

    更新日期：2017-09-01 00:00:00

  • Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

    abstract：:Breast cancer is the most common cancer among women. It is estimated that 7% of women who have breast cancer will develop a subsequent second independent breast tumor within 10 years of the first. The status of estrogen (ER), progesterone (PR) and human growth hormone (HER2) receptors, individually and as phenotypic c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0469-z

    authors： Brown M,Bauer K,Pare M

    更新日期：2010-02-01 00:00:00

  • Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

    abstract：:Familial aggregations of breast/ovarian cancer cases frequently depend on BRCA1/2 pathogenic mutations. Here we counselled 120 Italian breast/ovarian cancer families and selected 73 probands for BRCA1/2 mutation screening. Through this analysis we defined the prevalence of BRCA1/2 pathogenic mutations occurring in Ita...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9225-9

    authors： Giannini G,Capalbo C,Ristori E,Ricevuto E,Sidoni T,Buffone A,Cortesi E,Marchetti P,Scambia G,Tomao S,Rinaldi C,Zani M,Ferraro S,Frati L,Screpanti I,Gulino A

    更新日期：2006-11-01 00:00:00

  • Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

    abstract：PURPOSE:When combined with anthracyclines, the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) provides significant clinical benefit for women with HER2-overexpressing metastatic breast cancer. However, its use is limited by severe cardiotoxicity. To clarify whether myocardial HER2 and HER4 expression i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/b:brea.0000003916.39959.73

    authors： Fuchs IB,Landt S,Bueler H,Kuehl U,Coupland S,Kleine-Tebbe A,Lichtenegger W,Schaller G

    更新日期：2003-11-01 00:00:00

  • National consensus recommendations on patient-centered care for ductal carcinoma in situ.

    abstract：PURPOSE:The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS:Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older wer...

    journal_title：Breast cancer research and treatment

    pub_type： 共识发展会议,杂志文章,评审

    doi：10.1007/s10549-019-05132-z

    authors： Gagliardi AR,Wright FC,Look Hong NJ,Groot G,Helyer L,Meiers P,Quan ML,Urquhart R,Warburton R

    更新日期：2019-04-01 00:00:00

  • Clinical/genetic features in hereditary breast cancer.

    abstract：:Patients from hereditary breast cancer-prone (HBC) families provide one of the most powerful and potentially cost effective models for cancer prevention and control. Paradoxically, this opportunity is often missed in the clinical practice setting due, in part, to inattention to the family history and/or lack of knowle...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01810778

    authors： Lynch HT,Watson P,Conway TA,Lynch JF

    更新日期：1990-02-01 00:00:00

  • Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status.

    abstract：:Cell-mediated immune (CMI) responses to tumor-associated antigens (TAA) in the early postoperative period were examined for correlations with disease recurrence and survival in a 13-year-prospective study of 77 stage 1 and 2 breast cancer patients treated with modified radical or radical mastectomy alone. Among the 21...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006405504158

    authors： Mccoy JL,Rucker R,Petros JA

    更新日期：2000-04-01 00:00:00

  • New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.

    abstract：PURPOSE:Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphopenia which impairs it...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4380-8

    authors： Alshaker H,Wang Q,Srivats S,Chao Y,Cooper C,Pchejetski D

    更新日期：2017-10-01 00:00:00

  • Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

    abstract：:The NSABP B-30 trial addresses whether amenorrhea after adjuvant chemotherapy increases survival. Preliminary to the trial outcome analysis, we examined the incidence of amenorrhea and its relationship to symptoms and quality of life (QOL) in the standard-care arm of this adjuvant breast cancer trial. Premenopausal wo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-008-9937-0

    authors： Swain SM,Land SR,Ritter MW,Costantino JP,Cecchini RS,Mamounas EP,Wolmark N,Ganz PA

    更新日期：2009-01-01 00:00:00

  • Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.

    abstract：:Chromosomal instability is a known hallmark of many cancers. DNA polymerases represent a group of enzymes that are involved in the mechanism of chromosomal instability as they have a central function in DNA metabolism. We hypothesized that genetic variation in the polymerase genes may affect gene expression or protein...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1460-z

    authors： Varadi V,Bevier M,Grzybowska E,Johansson R,Enquist K,Henriksson R,Butkiewicz D,Pamula-Pilat J,Tecza K,Hemminki K,Lenner P,Försti A

    更新日期：2011-08-01 00:00:00

  • Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.

    abstract：PURPOSE:In order to better define the breast cancer (BC) genetic risk factors in men, a germline investigation was carried out on 81 Male BC cases by screening the 24 genes involved in BC predisposition, genome stability maintenance and DNA repair mechanisms by next-generation sequencing. METHODS:Germline DNAs were te...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05429-z

    authors： Scarpitta R,Zanna I,Aretini P,Gambino G,Scatena C,Mei B,Ghilli M,Rossetti E,Roncella M,Congregati C,Bonci F,Naccarato AG,Palli D,Caligo MA

    更新日期：2019-12-01 00:00:00

  • Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications.

    abstract：BACKGROUND:The objective was to determine the additional value of pathologic examination using three-level sectioning and immunocytokeratin (ICK) staining of sentinel lymph node (SN) biopsies in cT1-2N0M0 breast carcinoma patients regarding lymph node staging and eligibility of systemic therapy taking primary tumor cha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9434-2

    authors： Groen RS,Oosterhuis AW,Boers JE

    更新日期：2007-09-01 00:00:00

  • PALB2 mutations in German and Russian patients with bilateral breast cancer.

    abstract：:Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Patients with bilateral breast cancer constitute a valuable group for ge...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1290-4

    authors： Bogdanova N,Sokolenko AP,Iyevleva AG,Abysheva SN,Blaut M,Bremer M,Christiansen H,Rave-Fränk M,Dörk T,Imyanitov EN

    更新日期：2011-04-01 00:00:00

  • The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

    abstract：:The Neoadjuvant response index (NRI) has been proposed as a simple measure of downstaging by neoadjuvant treatment in breast cancer. It was previously found to predict recurrence-free survival (RFS) in triple-negative (TN) breast cancer. It was at least as accurate as the standard binary system, the absence or presenc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3510-4

    authors： Jebbink M,van Werkhoven E,Mandjes IA,Wesseling J,Lips EH,Vrancken Peeters MJ,Loo CE,Sonke GS,Linn SC,Falo Zamora C,Rodenhuis S

    更新日期：2015-08-01 00:00:00

  • Cultured cell lines from human breast cancer biopsies and xenografts.

    abstract：:Eighty-five breast cancer specimens were processed as part of a program in tumor acquisition, propagation, and preservation for biotherapy. Nine long-term culture cell lines were developed. Four cell lines were from solid tumor metastases, two lines were from pleural fluid specimens, and three were from xenograft tumo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806292

    authors： Lewko WM,Vaghmar R,Hubbard D,Moore M,He YJ,Chang L,Husseini S,Wallwork K,Thurman GB,Oldham RK

    更新日期：1990-12-01 00:00:00

  • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

    abstract：:Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab trea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-012-2003-y

    authors： Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T

    更新日期：2012-06-01 00:00:00

  • MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

    abstract：:The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary lymphatic spread in breast cancer patients. Biopsies from breast cancer (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9400-z

    authors： Bathen TF,Jensen LR,Sitter B,Fjösne HE,Halgunset J,Axelson DE,Gribbestad IS,Lundgren S

    更新日期：2007-08-01 00:00:00